Torthaí cuardaigh - Richard Iggo
- 1 - 20 toradh as 22 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
-
2
Regulation of p53 Stability and Function in HCT116 Colon Cancer Cells de réir Matthias D. Kaeser, Stéphanie Pébernard, Richard Iggo
Foilsithe / Cruthaithe 2004Artigo -
3
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. de réir Julian Gannon, R Greaves, Richard Iggo, David P. Lane
Foilsithe / Cruthaithe 1990Artigo -
4
Evidence of frequent recombination among human adenoviruses de réir Alexander N. Lukashev, Olga E. Ivanova, Tatiana P. Eremeeva, Richard Iggo
Foilsithe / Cruthaithe 2008Artigo -
5
Increased apoptosis induction by 121F mutant p53 de réir Elisabeth Saller, Edward Tom, Michèle Brunori, Michèle Otter, Anne Estreicher, David H. Mack, Richard Iggo
Foilsithe / Cruthaithe 1999Artigo -
6
Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract de réir François Waridel, Anne Estreicher, Luc Bron, Jean‐Michel Flaman, C Fontolliet, P Monnier, T Frebourg, Richard Iggo
Foilsithe / Cruthaithe 1997Artigo -
7
A rapid PCR fidelity assay de réir Jean‐Michel Flaman, Thierry Frébourg, Viviane Moreau, Françoise Charbonnier, Cosette Martin, Chikashi Ishioka, Stephen Friend, Richard Iggo
Foilsithe / Cruthaithe 1994Artigo -
8
Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants de réir Mitsuhiro Tada, Keiji Furuuchi, Masako Kaneda, Joe Matsumoto, Masato Takahashi, Atsuko Hirai, Yasuhide Mitsumoto, Richard Iggo, Tetsuya Moriuchi
Foilsithe / Cruthaithe 2001Artigo -
9
Cell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses de réir Connie Chao, Manfred Hergenhahn, Matthias D. Kaeser, Zhiqun Wu, Shinichi Saito, Richard Iggo, Monica Hollstein, Ettore Appella, Yang Xu
Foilsithe / Cruthaithe 2003Artigo -
10
p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements de réir Paola Campomenosi, Paola Monti, Anna Aprile, Angelo Abbondandolo, Thierry Frébourg, Barry Gold, Tim Crook, Alberto Inga, Michael A. Resnick, Richard Iggo, Gilberto Fronza
Foilsithe / Cruthaithe 2001Artigo -
11
Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter de réir Inge Peerlinck, Andrew Merron, Patrick Baril, Sophie Conchon, Pilar Martín‐Duque, Cécilia Hindorf, Jerome Burnet, Miguel Quintanilla, Mohan Hingorani, Richard Iggo, Nicholas R. Lemoine, Kevin J. Harrington, Georges Vassaux
Foilsithe / Cruthaithe 2009Artigo -
12
Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations de réir Julie Massé, Caroline Truntzer, Romain Boidot, Emmanuel Khalifa, Gaëlle Pérot, Valérie Velasco, Laétitia Mayeur, Claire Billerey-Larmonier, Larry Blanchard, H. Charitansky, Isabelle Soubeyran, Richard Iggo, Laurent Arnould, Gaëtan MacGrogan
Foilsithe / Cruthaithe 2019Artigo -
13
Identification of molecular apocrine breast tumours by microarray analysis de réir Pierre Farmer, Hervé Bonnefoi, Véronique Becette, M. Tubiana-Hulin, P. Fumoleau, Denis Larsimont, Gaëtan MacGrogan, Jonas Bergh, David Cameron, Daniel R. Goldstein, Stephan Duss, A-L Nicoulaz, Maryse Fiche, Cathrin Brisken, Mauro Delorenzi, Richard Iggo
Foilsithe / Cruthaithe 2005Artigo -
14
Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response de réir Marion Chapellier, Élodie Bachelard-Cascales, Xenia Schmidt, Flora Clément, Isabelle Treilleux, E. Delay, Alexandre Jammot, Christine Ménétrier‐Caux, Gaëtan Pochon, Roger Besançon, Thibault Voeltzel, Claude Caron de Fromentel, Christophe Caux, Jean‐Yves Blay, Richard Iggo, Véronique Maguer‐Satta
Foilsithe / Cruthaithe 2015Artigo -
15
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations de réir Guillaume Banneau, Mickaël Guedj, Gaëtan MacGrogan, Isabelle de Mascarel, Valérie Velasco, Renaud Schiappa, Valérie Bonadona, Albert David, Catherine Dugast, Brigitte Gilbert‐Dussardier, Olivier Ingster, P. Vabres, F. Caux, Aurélien de Reyniès, Richard Iggo, Nicolas Sévenet, Françoise Bonnet, Michel Longy
Foilsithe / Cruthaithe 2010Artigo -
16
RETRACTED: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial de réir Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, L. Mauriac, Mario Campone, M. Tubiana-Hulin, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Véronique Becette, Pierre Farmer, Sylvie André, Chaitanya R. Acharya, Sayan Mukherjee, David Cameron, Jonas Bergh, Joseph R. Nevins, Richard Iggo
Foilsithe / Cruthaithe 2007Artigo -
17
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial de réir Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, L. Mauriac, P. Fumoleau, Étienne Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Khalil Zaman, Tanja Čufer, Alain Lortholary, Elisabet Lidbrink, Sylvie André, Saskia Litière, Lissandra Dal Lago, Véronique Becette, David Cameron, Jonas Bergh, Richard Iggo
Foilsithe / Cruthaithe 2011Artigo -
18
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial de réir Hervé Bonnefoi, Florence Lerebours, Marina Pulido, Mónica Arnedos, Olivier Trédan, Florence Dalenc, Séverine Guiu, Luís Teixeira, Delphine Mollon, Christelle Levy, Benjamin Verret, Heba Dawood, Laura Deiana, Marie‐Ange Mouret‐Reynier, Paule Augereau, Jean-Luc Canon, Noémie Huchet, C. Guyonneau, Jérôme Lemonnier, Gaëtan MacGrogan, Anthony Gonçalves, Élodie Darbo, Richard Iggo
Foilsithe / Cruthaithe 2025Artigo -
19
Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer de réir Rayzel C. Fernandes, John Toubia, Scott L. Townley, Adrienne R. Hanson, B. Kate Dredge, Katherine A. Pillman, Andrew G. Bert, Jean M. Winter, Richard Iggo, Rajdeep Das, Daisuke Obinata, Shahneen Sandhu, Gail P. Risbridger, Renea A. Taylor, Mitchell G. Lawrence, Lisa M. Butler, Amina Zoubeidi, Philip A. Gregory, Wayne D. Tilley, Theresa E. Hickey, Gregory J. Goodall, Luke A. Selth
Foilsithe / Cruthaithe 2021Artigo -
20
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer de réir Theresa E. Hickey, Luke A. Selth, Kee Ming Chia, Geraldine Laven‐Law, Heloisa Milioli, Daniel Roden, Shalini Jindal, Mun N. Hui, Jessica Finlay-Schultz, Esmaeil Ebrahimie, Stephen N. Birrell, Suzan Stelloo, Richard Iggo, Sarah Alexandrou, C. Elizabeth Caldon, Tarek M. Abdel-Fatah, Ian O. Ellis, Wilbert Zwart, Carlo Palmieri, Carol A. Sartorius, Alexander Swarbrick, Elgene Lim, Jason S. Carroll, Wayne D. Tilley
Foilsithe / Cruthaithe 2021Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Biology
Genetics
Gene
Cancer
Cancer research
Medicine
Internal medicine
Breast cancer
Molecular biology
Mutant
Cell biology
Pathology
Oncology
Carcinogenesis
Mdm2
Prostate cancer
Transcription factor
Wild type
Androgen receptor
Apoptosis
Computational biology
DNA
DNA damage
Gene expression
Mutation
Adenoviridae
Anthracycline
Apocrine
Biochemistry
Bioinformatics